0000000000700648

AUTHOR

Bella A.

showing 5 related works from this author

Has VZV epidemiology changed in Italy? Results of a seroprevalence study

2017

The aim of the study was to evaluate if and how varicella prevalence has changed in Italy. In particular a seroprevalence study was performed, comparing it to similar surveys conducted in pre-immunization era. During 2013–2014, sera obtained from blood samples taken for diagnostic purposes or routine investigations were collected in collaboration with at least one laboratory/center for each region, following the approval of the Ethics Committee. Data were stratified by sex and age. All samples were processed in a national reference laboratory by an immunoassay with high sensitivity and specificity. Statutory notifications, national hospital discharge database and mortality data related to V…

Male0301 basic medicinePediatricsCross-sectional studySeroprevalenceSettore MED/42 - Igiene Generale E ApplicataAntibodies Viralmedicine.disease_causeChickenpox0302 clinical medicineChickenpox; Immunization; Seroprevalence; Surveillance; Varicella-Zoster Virus; Adolescent; Adult; Age Factors; Aged; Aged 80 and over; Antibodies Viral; Chickenpox; Child; Child Preschool; Cross-Sectional Studies; Female; Humans; Infant; Infant Newborn; Italy; Male; Middle Aged; Seroepidemiologic Studies; Young Adult; Immunology and Allergy; Immunology; PharmacologySeroepidemiologic StudiesEpidemiology80 and overImmunology and AllergyAge FactorViral030212 general & internal medicineYoung adultChildskin and connective tissue diseasesAged 80 and overSurveillanceChickenpoxVaricella-Zoster ViruAge FactorsMiddle AgedResearch PapersItalyChild PreschoolFemaleChickenpox; Immunization; Seroprevalence; Surveillance; Varicella-Zoster Virus; Immunology and Allergy; Immunology; PharmacologyHumanAdultmedicine.medical_specialtyAdolescent030106 microbiologyImmunologyAntibodiesNOYoung Adult03 medical and health sciencesChickenpox; Immunization; Seroprevalence; Surveillance; Varicella-Zoster VirusmedicineHumansSeroprevalencePreschoolAgedCross-Sectional StudiePharmacologybusiness.industrySeroepidemiologic StudieInfant NewbornVaricella zoster virusInfantSeroepidemiologic StudiesNewbornmedicine.diseaseVaricella-Zoster VirusCross-Sectional StudiesImmunizationImmunizationsense organsChickenpox Immunization Seroprevalence Surveillance Varicella-Zoster Virus Immunology and Allergy Immunology Pharmacologybusiness
researchProduct

Prevalence and risk factors for Enterobacteriaceae in patients hospitalized with community-acquired pneumonia

2020

N.J.S. is partially funded by the Department of Veterans Affairs, Quality Enhancement Research Initiative (QUERI) Partnered Evaluation Initiative Grant (HX002263-01A1). Background and objective : Enterobacteriaceae (EB) spp. family is known to include potentially multidrug-resistant (MDR) microorganisms, and remains as an important cause of community-acquired pneumonia (CAP) associated with high mortality. The aim of this study was to determine the prevalence and specific risk factors associated with EB and MDR-EB in a cohort of hospitalized adults with CAP. Methods : We performed a multinational, point-prevalence study of adult patients hospitalized with CAP. MDR-EB was defined when ≥3 ant…

MalePulmonary and Respiratory Medicinemedicine.medical_specialtycommunity-acquired pneumoniaCommunity-acquired pneumoniaEnterobacteriaceae ; community-acquired pneumonia ; multidrug-resistance ; prevalence ; risk factorsInternational CooperationprevalenceMultidrug-resistanceMicrobial Sensitivity TestsSettore MED/10 - Malattie Dell'Apparato RespiratorioResearch initiativeE-NDASCohort StudiesCommunity-acquired pneumoniaSDG 3 - Good Health and Well-beingEnterobacteriaceaePrevalenceHumansMedicinerisk factorsIn patientRisk factorVeterans Affairshealth care economics and organizationsAgedbusiness.industryEnterobacteriaceae InfectionsQR Microbiologymedicine.diseasecommunity-acquired pneumonia; Enterobacteriaceae; multidrug-resistance; prevalence; risk factorsmultidrug-resistanceDrug Resistance MultiplehumanitiesQuality enhancementQRCommunity-Acquired InfectionsHospitalizationRisk factorsrisk factorFamily medicineFemalebusinessRisk assessmentCohort study
researchProduct

Carga y factores de riesgo para la neumonía adquirida en la comunidad de Pseudomonas aeruginosa : un estudio multinacional de prevalencia puntual de …

2018

Pseudomonas aeruginosa is a challenging bacterium to treat due to its intrinsic resistance to the antibiotics used most frequently in patients with community-acquired pneumonia (CAP). Data about the global burden and risk factors associated with P. aeruginosa-CAP are limited. We assessed the multinational burden and specific risk factors associated with P. aeruginosa-CAP. We enrolled 3193 patients in 54 countries with confirmed diagnosis of CAP who underwent microbiological testing at admission. Prevalence was calculated according to the identification of P. aeruginosa. Logistic regression analysis was used to identify risk factors for antibiotic-susceptible and antibiotic-resistant P. aeru…

Pneumonia Pseudomonas aeruginosaMaleantibiotic resistanceInternationalityCross-sectional studybacterial colonizationvery elderlyPrevalenceDrug ResistanceDrug resistancePneumònia adquirida a la comunitatPseudomonas aeruginosa community acquired pneumoniaPulmonary Disease Chronic Obstructive0302 clinical medicineTracheostomyCommunity-acquired pneumoniaRisk FactorsEpidemiology80 and overPrevalenceMedicineCommunity-Acquired Infection030212 general & internal medicineAged 80 and overCross InfectionadultarticleBacterialMiddle AgedAntibiotic coverageBronchiectasisCommunity-Acquired Infectionshospital patientpriority journalrisk factorAged; Aged 80 and over; Bronchiectasis; Community-Acquired Infections; Cross Infection; Cross-Sectional Studies; Drug Resistance Bacterial; Female; Humans; Internationality; Logistic Models; Male; Middle Aged; Pneumonia Bacterial; Prevalence; Pseudomonas aeruginosa; Pulmonary Disease Chronic Obstructive; Risk Factors; TracheostomyPseudomonas aeruginosaInfectious diseasesFemaleHumanPulmonary and Respiratory Medicinemedicine.medical_specialtyChronic ObstructiveCommunity-acquired pneumoniaLogistic ModelAdmissionSettore MED/10 - Malattie Dell'Apparato Respiratoriochronic lung diseasePulmonary Disease03 medical and health sciencesBronchiectasiInternal medicinePseudomonasDrug Resistance BacterialPneumonia BacterialHumanscontrolled studyhumanAgedCross-Sectional StudieBronchiectasisbusiness.industryRisk Factorcommunity acquired pneumoniaPneumoniamedicine.diseaselogistic regression analysismajor clinical studyantibiotic sensitivityPneumoniahospital admissionCross-Sectional StudiesLogistic Models030228 respiratory systemmicrobiological examinationbusinesschronic obstructive lung disease
researchProduct

Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021

2021

COVID study groups - PORTUGAL: Portuguese Laboratory Network for the Diagnosis of COVID-19 and Public Health Department of the Health Administrative Regions, Physicians that provided data and samples from suspected cases and SARS-CoV-2 genetic characterization. INSA laboratory team for the diagnosis of SARS-CoV-2. Algarve Biomedical Center and Unilabs. We compared 19,207 cases of SARS-CoV-2 variant B.1.1.7/S gene target failure (SGTF), 436 B.1.351 and 352 P.1 to non-variant cases reported by seven European countries. COVID-19 cases with these variants had significantly higher adjusted odds ratios for hospitalisation (B.1.1.7/SGTF: 1.7, 95% confidence interval (CI): 1.0-2.9; B.1.351: 3.6, 95…

Infecções Respiratórias2019-20 coronavirus outbreakmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Critical CareEpidemiologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)variants of concernSettore MED/42 - Igiene Generale E Applicata03 medical and health sciences0302 clinical medicineVirologyInternal medicineMedicineHumansIntensive care admission030212 general & internal medicineCOVID-19; Europe; SARS-CoV-2; surveillance; variants of concern; Critical Care; Europe; Humans; COVID-19; SARS-CoV-2Surveillancebusiness.industrySARS-CoV-2030503 health policy & servicesPublic Health Environmental and Occupational HealthCOVID-19Odds ratioConfidence intervalEuropesurveillanceVariants of ConcernCOVID-19 Europe SARS-CoV-2 surveillance variants of concern0305 other medical sciencebusinessRapid CommunicationHuman
researchProduct

Co-circulation of the two influenza B lineages during 13 consecutive influenza surveillance seasons in Italy, 2004-2017

2019

AbstractBackgroundSince 1985, two antigenically distinct lineages of influenza B viruses (Victoria-like and Yamagata-like) have circulated globally. Trivalent seasonal influenza vaccines contain two circulating influenza A strains but a single B strain and thus provide limited immunity against circulating B strains of the lineage not included in the vaccine. In this study, we describe the characteristics of influenza B viruses that caused respiratory illness in the population in Italy over 13 consecutive seasons of virological surveillance, and the match between the predominant influenza B lineage and the vaccine B lineage, in each season.MethodsFrom 2004 to 2017, 26,886 laboratory-confirme…

0301 basic medicineInfluenza virological surveillance Influenza B virus Victoria lineage Yamagata lineage Vaccine matchmedicine.medical_specialtyLineage (evolution)PopulationInfluenza B viruHemagglutinin (influenza)Vaccine matchSettore MED/42 - Igiene Generale E ApplicataViruslcsh:Infectious and parasitic diseases03 medical and health sciences0302 clinical medicineMedical microbiologyImmunityRetrospective StudieInfluenza HumanmedicineHumanslcsh:RC109-216030212 general & internal medicineeducationPhylogenyRetrospective Studieseducation.field_of_studybiologyStrain (biology)Victoria lineageInfluenza B virus; Influenza virological surveillance; Italy; Vaccine match; Victoria lineage; Yamagata lineageVirologyInfluenzaInfluenza B virus030104 developmental biologyInfectious DiseasesInfluenza virological surveillanceParasitologyItalyInfluenza VaccinesInfluenza virological surveillance Influenza B virus Victoria lineage Yamagata lineage Vaccine match ItalyEpidemiological Monitoringbiology.proteinInfluenza B virus; Influenza virological surveillance; Italy; Vaccine match; Victoria lineage; Yamagata lineage; Epidemiological Monitoring; Humans; Influenza B virus; Influenza Vaccines; Influenza Human; Italy; Phylogeny; Retrospective Studies; SeasonsSeasonsInfluenza VaccineYamagata lineageResearch ArticleHuman
researchProduct